Stattic

• CAT Number: I002533
• CAS Number: 19983-44-9
• Molecular Formula: C₈H₅NO₄S
• Molecular Weight: 211.19
• Purity: ≥95%
• Synonyms: 6-nitro-1-benzothiophene 1,1-dioxide
• Target: STAT
• Solubility: 10 mM in DMSO
• Storage: 3 years -20C powder
• InChI: InChI=1S/C8H5NO4S/c10-9(11)7-2-1-6-3-4-14(12,13)8(6)5-7/h1-5H
• InChIKey: ZRRGOUHITGRLBA-UHFFFAOYSA-N
• SMILES: C1=CC(=CC2=C1C=CS2(=O)=O)[N+](=O)[O-]

Stattic is a potent inhibitor of STAT3, used for cancer treatment.IC50 value:Target:In vitro: Stattic inhibits STAT3 phosphorylation (Y705) in ALDH+ and D44+/CD24+ subpopulations of Panc-1 and HPAC pancreatic cancer cell lines at a higher concenration (20 μM). Stattic selectively inhibited P-STAT3 as demonstrated by the lack of inhibition of P-ERK1/2 in both ALDH+ and CD44+/CD24+ subpopulations of Panc-1 and HPAC. Stattic inhibita STAT3 downstream targets in ALDH+ and CD44+/CD24+ subpopulations of pancreatic cancer cells[1]. Stattic reduces the LPS-induced expression of ICAM-1 and VCAM-1, and STAT3 phosphorylation[3].In vivo:

Reference

[1]. Held, D.M., et al., Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. J Biol Chem, 2006. 281(35): p. 25712-22.
[2]. Young, S.D., et al., L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother, 1995. 39(12): p. 2602-5.
[3]. Grobler, J.A., et al., HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem, 2007. 282(11): p. 8005-10.
[4]. Gatch, M.B., et al., The HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacology, 2013. 38(12): p. 2373-84.
[5]. Adjene, J.O., P.S. Igbigbi, and E.U. Nwose, Histological effects of chronic administration of efavirenz on lateral geniculate body of adult Wistar rats. N Am J Med Sci, 2010. 2(1): p. 1-4.